Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million
- First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million
Cash and Investments
At March 31, 2024, Acadia’s cash, cash equivalents and investment securities totaled $470.5 million, compared to $438.9 million at December 31, 2023.
Full Year 2024 Financial Guidance
Acadia is reiterating all of its 2024 guidance provided on February 27, 2024.
https://www.businesswire.com/news/home/20240508446041/en/
- DAYBUE net product sales guidance in the range of $370 to $420 million.
- NUPLAZID net product sales guidance in the range of $560 to $590 million.
- R&D expense in the range of $305 to $325 million.
- SG&A expense in the range of $455 to $480 million.
Acadia Pharmaceuticals Reports First Quarter 2024 Financial...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.98 |
Change
0.180(0.91%) |
Mkt cap ! $2.551B | |||
| Open | High | Low | Value | Volume |
| $19.95 | $20.18 | $19.59 | $6.383M | 319.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 364 | $19.91 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 579 | 1 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.99 |
Change
0.180 ( 0.78 %) |
||||
| Open | High | Low | Volume | ||
| $19.99 | $20.15 | $19.60 | 82143 | ||
| Last updated 15.59pm 18/06/2024 ? | |||||
| NEU (ASX) Chart |